BioTuesdays
Hepion Logo

AGP starts Hepion at buy; PT $4

Alliance Global Partners launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with a “buy” rating and price target of $4. Shares of Hepion closed at 73 cents on Jan. 31. Analyst James Molloy writes that his...

Editas-Logo

Cantor starts Editas Medicine at OW; PT $15

Cantor Fitzgerald initiated coverage of Editas Medicine (NASDAQ:EDIT) with an “overweight” rating and 12-month price target of $15. The stock closed at $9.35 on Jan. 31. Editas is a clinical-stage gene editing company...

Precigen-Logo

Cantor ups Precigen PT after R&D event

Cantor Fitzgerald raised its price target for Precigen (NASDAQ:PGEN) to $10 from $7 after the company held an R&D event to showcase safety and efficacy data from a Phase 1 trial. The stock closed at $1.64 on Jan. 27...

Celularity-Logo

HCW slashes Celularity PT on pipeline priority changes

H.C. Wainwright reduced its price target for Celularity (NASDAQ:CELU) to $2.50 from $15, but reiterated a “buy” rating, after the company unveiled a strategic shift in its pipeline. The stock closed at $1.05 on Jan. 27...

Dawson James starts Genprex at buy; PT $3

Dawson James Securities initiated coverage of Genprex (NASDAQ:GNPX) with a “buy” rating and $3 price target. The stock closed at $1.34 on Jan. 27. Genprex is a clinical-stage gene therapy company pioneering the...

Compass-Logo

Stifel starts Compass Therapeutics at buy; PT $9

Stifel initiated coverage of Compass Therapeutics (NASDAQ:CMPX) with a “buy” rating and price target of $9. The stock closed at $3.95 on Jan. 26. “We believe the recent presentation at ASCO-GI 2023 of updated results...

Zomedica Pharmaceuticals

Dawson James starts Zomedica at buy; PT $6

Dawson James initiated coverage of Zomedica (NYSEA:ZOM) with a “buy” rating and price target of $6. The stock closed at 20 cents on Jan. 5. Analyst Jason Kolbert writes that Zomedica is positioning itself as a leading...

Sight-Sciences-Logo

Stifel ups Sight Sciences to buy after survey

Stifel upgraded Sight Sciences (NASDAQ:SGHT) to “buy” from “ hold” and raised its price target to $15 from $10 after a survey of 41 minimally invasive glaucoma surgery (MIGS)-trained ophthalmologists “gives us increased...

HCW starts Poseida Therapeutics at buy; PT $15

H.C. Wainwright initiated coverage of Poseida Therapeutics (NASDAQ:PSTX) with a “buy” rating and $15 price target. The stock closed at $5.79 on Jan. 2. Poseida is a clinical-stage biopharmaceutical company focused on...

BTIG starts Sophia Genetics at buy; PT $6

BTIG initiated coverage of Sophia Genetics (NASDAQ:SOPH) with a “buy” rating and $6 price target. The stock price closed at $2.06 on Dec. 30. Sophia is a rapidly growing, global healthcare technology company that sells...

Ardelyx Logo

Cantor ups Ardelyx PT to $3 after FDA update

Cantor Fitzgerald raised its price target for Ardelyx (NASDAQ:ARDX) to $3 from $1.60 but maintained a “neutral” rating after a label update from the FDA. The stock closed at $2.51 on Dec. 28. Ardelyx announced that the...

X4 Pharma

Cantor starts X4 Pharma at OW; PT $3

Cantor Fitzgerald launched coverage of X4 Pharmaceuticals (NASDAQ:XFOR) with an “overweight” rating and a 12-month price target of $3. The stock closed at 80 cents on Dec. 22. X4 is a clinical-stage biopharmaceutical...

MediWound Logo

Maxim starts MediWound at buy; PT $25

Maxim Group initiated coverage of MediWound (NASDAQ:MDWD) with a “buy” rating and $25 price target. The stock closed at $11 on Dec. 21. MediWound is a commercial-stage company developing a bromelain-based platform to...

New-Amsterdam-Logo

SVB starts NewAmsterdam Pharma at OP; PT $19

SVB Securities initiated coverage of NewAmsterdam Pharma (NASDAQ:NAMS) with an “outperform” rating and $19 price target. The stock closed at $11.31 on Dec. 19. “We believe there is a place for NewAmsterdam’s...

Acurx-Pharma-Logo

HCW starts Acurx Pharma at buy; PT $14

H.C. Wainwright launched coverage of Acurx Pharmaceuticals (NASDAQ:ACXP) with a “buy” rating and $14 price target. The stock closed at $3.83 on Dec. 16. Acurx is a clinical stage biopharmaceutical company focused on...